Slide 1: Results 1H25
Results 1H25 Analyst & Investor call An Steegen / Ann Desender July 16th, 2025 - Kortrijk 1
Slide 2: Preliminary notes
Preliminary notes The statutory auditor has confirmed that the audit, which is substantially complete, has not to date revealed any material misstatement in the draft consolidated accounts, and that the accounting data reported in the press release is consistent, in all material respects, with the d
Slide 3: Solid profitable growth, confirming outlook
Solid profitable growth, confirming outlook Group results 1H25 5% Sales & Orders growth 10.6% EBITDA margin 2.5ppts Gross profit up 0.3 ppts; impact tariffs offset by better Growth driven by Entertainment and Healthcare product mix; OPEX contained Orderbook strengthened +3% yoy Free cash flow of € 2
Slide 4: Positive evolution on all group KPIs
Positive evolution on all group KPIs 5% sales growth, step up in EBITDA to 10.6% vs. 1H24 ORDERS +5% • Order and sales growth +5% € 487.5m • Sales growth driven by Entertainment and Healthcare SALES • Orderbook @ € 548.4m, +3% year-over-year € 454.4m +5% Gross profit • EBITDA at 10.6%, ↑ 2.5 ppts yo
Slide 5: 1H25 - Solid sales growth, rebound in EMEA
1H25 - Solid sales growth, rebound in EMEA Sales growth driven by Entertainment in both EMEA & Americas, and by Healthcare Americas BY REGION S: sales O: orders S: 10% S: 5% S: -7% O: -4% O: 27% O: -3% Americas 49% EMEA 32% APAC 19% BY DIVISION • Healthcare (+5% yoy): driven by Surgical & Modality i
Slide 6: EBITDA step up to 10.6% of sales
EBITDA step up to 10.6% of sales Sales growth, stable gross profit margin and lower OPEX Sales Gross Profit R&D S&M G&A Other Margin 48 10.6% of sales 35 8.1% of sales Gross profit improvement Lower result Opex controlled with revenue growth & China JV R&D at 13% of sales, higher better product mix,
Slide 7: Net income landing > 5% of sales
Net income landing > 5% of sales Net income +14.3m year-over-year (in millions of euro) 1H25 Δ24 EBITDA 48.0 12.8 % Sales Change (ppts) 10.6% 2.5 Depreciations & amortizations (22.3) (0.5) Restructuring (2.0) 5.8 • Depreciations & amortizations stable EBIT 23.7 18.1 Interest and taxes (1.9) (3.3) •
Slide 8: 1H25 Free cash flow @ € 21.4m, up 6.8m yoy
1H25 Free cash flow @ € 21.4m, up 6.8m yoy Net operating cash flow at € 45.1m, up 5.6m yoy Working capital at 12.2% of sales € 21.4m Working capital reduced with 29% versus a year ago DSO at 64 days in balance with DPO at 63 days Free cash flow Inventories remain focus area, turns at 2.2 (vs 2.1 at
Slide 9: Mitigating trade policies and currency exchange rates
Mitigating trade policies and currency exchange rates Current view Mitigating actions Competitive situation • Volatile US trade tariffs during 2Q25, • Relocation of production • 49% of 1H25 sales were in including temporary measures between China and Europe, the Americas, US is largest where appropr
Slide 10: Further improving on our sustainability KPI’s
Further improving on our sustainability KPI’s Eco labelled revenues Net Promotor Score Exceeding the target of 50 Good progress towards 75% 70% 56 Improvement led by Diagnostic Driven by new products and Imaging, Cinema & Control growth in software Rooms +2% vs FY24 Stricter methodology based on +2
Slide 11: Divisional Update Half year 2025
Divisional Update Half year 2025 11
Slide 12: Healthcare
Healthcare (in millions of euro) Healthcare 1H25 Δ 1H24 Strong growth in Surgical & Modality; Digital Pathology gaining traction Orders 141.6 +15% Margin expansion driven by improved mix and software momentum Sales 137.6 +5% EBITDA 17.2 +50% Diagnostic Surgical & % Sales 12.5% +3.7 ppts Imaging Moda
Slide 13: Enterprise
Enterprise (in millions of euro) Enterprise 1H25 Δ 1H24 ClickShare rebound with double-digit growth Orders 109.5 -1% Control Rooms impacted by US uncertainties and LED pressure Sales 107.6 -5% EBITDA 8.6 +79% % Sales 8.0% +3.8 ppts Meeting Experience Control Rooms • Double-digit growth in orders and
Slide 14: Entertainment
Entertainment (in millions of euro) Entertainment 1H25 Δ 1H24 Momentum in Cinema with new large contracts and launch of HDR Orders 236.4 +3% Solid sales growth in Immersive Experience, driven by new products Sales 209.3 +10% EBITDA 22.2 +17% Immersive % Sales 10.6% +0.7 ppts Cinema Experience • Sale
Slide 15: Outlook & closing
Outlook & closing 15
Slide 16: Focus areas for 2025
Focus areas for 2025 Barco continues its growth in new products, adjacencies and software, despite high volatility in macro-economics New product Continuing Efficiencies from Expansion in introductions transformation Focused further factories investments adjacencies and delivering growth in automati
Slide 17: Outlook 2025
Outlook 2025 The following statements are forward looking on a like-for-like basis and actual results may differ materially Geopolitical instability, combined with high volatility in trade policies and currency exchange rates, continue to impact market demand and visibility. Assuming no major advers
Slide 18: Q&A
Q&A 18
Slide 19: Stay tuned
Stay tuned Financial calendar 2025 Wednesday 15 October Thursday 23 October Trading update 3Q25 Capital Markets Day 2025 More information? Please visit our webpage https://www.barco.com/en/about/investors Barco’s Capital Markets Day 2025 will be on October 23rd in Barco’s HQ in Kortrijk, Belgium 19
Slide 20: Visioneering a bright tomorrow
Visioneering a bright tomorrow